The respected, nonpartisan Congressional Budget Office (CBO) doesn’t often study the 340B drug discount program; therefore stakeholders need to take its findings seriously and closely examine them when the situation arises.  

Reports from agencies like CBO often have a lot of influence, particularly ones that assess the budgetary impact of such an important program as 340B. Read More >